614-864-4919 info@sermonixpharma.com
sermonix pharmaceutical
  • About
    • Company Overview
    • Management Team
    • Board of Directors
    • Oncology Steering Committee
    • Partners & Collaborations
  • Breast Cancer
  • Lasofoxifene
  • For Patients
    • The ELAINE Study
    • The ELAINE 2 Study
  • News & Media
    • News
    • Media
  • Medical Meetings
  • Contact
Select Page

Sermonix to Present Poster on Lasofoxifene, CDK 4/6 Inhibitor Combination for AACR Virtual Annual Meeting

by Sermonix Pharmaceuticals | Jun 18, 2020 | News

University of Chicago preclinical study compared combination to that of fulvestrant and palbociclib in a mouse intraductal model with cells carrying Y537S ESR1 mutations. Findings will be shared June 22 as part of AACR’s Clinical Endocrinology 2 session. COLUMBUS,...

Recent Posts

  • Sermonix Pharmaceuticals Completes Enrollment of Phase 2 Clinical Trial Collaboration Studying …
  • Sermonix Pharmaceuticals Announces Breast Cancer Research Publication of Preclinical Lasofoxifene Study in Endocrine-Resistant Breast Cancer
  • Sermonix Pharmaceuticals Project With Huntsman Cancer Institute Researcher to Investigate Potential Effects of Lasofoxifene on ESR1 Mutations in Endometrial Cancer
  • Sermonix Pharmaceuticals Names Dr. Elizabeth Garner to Its Board of Directors
  • Sermonix to Present Poster on Phase 2 Study of Lasofoxifene in Combination with Eli Lilly and Company’s Abemaciclib at Virtual San Antonio Breast Cancer Symposium 2020

Recent Comments

    Archives

    • June 2021
    • May 2021
    • April 2021
    • January 2021
    • December 2020
    • October 2020
    • September 2020
    • July 2020
    • June 2020
    • December 2019
    • September 2019
    • June 2019
    • May 2019
    • April 2019
    • March 2019

    Categories

    • News

    Meta

    • Log in
    • Entries RSS
    • Comments RSS
    • WordPress.org

    © 2021 Sermonix Pharmaceuticals